NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Recursion Pharmaceuticals, Inc. RXRX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$74.7M
▲ 26.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-59.5%
Net margin · FY25
-863.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 74.7M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 863 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-59.5%
Return on equity, FY2025
ROE
Operating margin-867.9%
Net margin-863.4%
Return on assets-44.1%
Each USD of equity lost 60 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+79.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+23.3%
+79.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.5B
total assets, end of FY2025
Total assetsUSD 1.5B
EquityUSD 1.1B
CashUSD 743.3M
Gross debtUSD 9.6M
Net debtUSD -733.7M
Current ratio5.50×
The company holds more cash than debt.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.6
−0.5
−0.4
−0.2
−0.2
−0.1
−0.1
EBITDA $B
−0.6
−0.4
−0.3
−0.2
−0.2
−0.1
−0.1
Income tax $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.6
−0.5
−0.3
−0.2
−0.2
−0.1
−0.1
EPS, diluted $
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−59.5
−61.9
−69.1
−46.6
−110.8
·
·
Shares out B
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed